Medimmune Limited

Medlmmune Limited

Timothy Pabst

Alan Hunter

Xiangyang Wang

Christopher D Thompson

Liu Tie

Yiming Li

Michaela Wendeler

Mariko Fonseca

Thomas Linke

Robert Strouse

Jihong Wang

Guoling Xi

Andrew Fulton

Kendall Carey

Johnson Varghese

The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.

Method of purifying albumin-fusion proteins

The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.

Methods of producing immunoconjugates

The present application relates to methods for purifying recombinant coagulation factor proteins, including for example, prothrombin (Factor II). In embodiments, the methods provide purified prothrombin that exhibit increased bioactivity and reduced levels of thrombin, thereby increasing the safety of the prothrombin. Also provided are purified recombinant coagulation factor proteins.

Methods for processing coagulation factors

Growing community of inventors

Gaithersburg, MD, United States of America

Timothy Pabst